PLGA (poly(lactic-co-glycolic acid) fiber-microsphere dual-drug-loaded composite scaffold and preparation method of PLGA fiber-microsphere dual-drug-loaded composite scaffold
A composite stent and dual drug-loading technology, which is applied in the fields of medical science and prosthesis, can solve problems such as complex methods, and achieve the effects of simple methods, avoiding inactivation, and high biological safety
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0024] Example 1: 200 mg of PLGA (100 kDa, 75 / 25) was weighed, and 50 mg of simvastatin was dissolved in a mixed solvent of dichloromethane and N,N-dimethylformamide (2:1, v / v) , sealed, left at 4°C overnight, magnetically stirred for 4h, vortexed for 10min, ultrasonicated for 30s to eliminate air bubbles, and a uniform electrospinning solution containing simvastatin was obtained; PLGA (50kDa, 50 / 50) and BMP-2 were prepared uniformly electrospray solution. The specific method is as follows: dissolve 60 mg of PLGA (50kDa, 50 / 50) in dichloromethane, seal it, let stand at 4°C overnight, stir magnetically for 4 hours, vortex for 10 minutes, and then sonicate for 45 seconds to eliminate air bubbles to obtain a PLGA solution; 2 200ug was dissolved in 4mL PBS buffer solution; 100μL of BMP-2-containing PBS solution was added to the PLGA solution, in an ice bath, ultrasonicated for 5s, stopped for 5s, and then ultrasonicated for 5s, repeated 10 times, emulsified to obtain a uniform BMP...
Embodiment 2
[0025]Example 2: 200 mg of PLGA (100 kDa, 75 / 25) was weighed, and 20 mg of lovastatin was dissolved in a mixed solvent of dichloromethane and N,N-dimethylformamide (2:1, v / v) , sealed, left standing overnight at 0°C, magnetically stirred for 5.5h, vortexed for 15min, and ultrasonicated for 45s to eliminate air bubbles to obtain a uniform electrospinning solution containing lovastatin; PLGA (55kDa, 50 / 50) and EGF were prepared into a uniform EFI solution. The specific method is as follows: Dissolve 60 mg of PLGA (55kDa, 50 / 50) in dichloromethane, seal it, let it stand overnight at 0°C, stir magnetically for 5 hours, vortex for 10 minutes, and then sonicate for 60 seconds to eliminate bubbles to obtain a PLGA solution; EGF 10ug Dissolve in 10mL of PBS buffer solution; add 200μL of EGF-containing PBS solution to PLGA solution, in ice bath condition, sonicate for 5s, stop for 5s, and then sonicate for 5s, repeat 8 times, and emulsify to obtain a uniform electrospray solution conta...
Embodiment 3
[0026] Example 3: 200 mg of PLGA (120 kDa, 75 / 25) was weighed, and 10 mg of pravastatin was dissolved in a mixed solvent of dichloromethane and N, N-dimethylformamide (2:1, v / v) , sealed, left standing overnight at 0°C, magnetically stirred for 5h, vortexed for 15min, ultrasonicated for 60s to eliminate air bubbles, and a uniform electrospinning solution containing pravastatin was obtained; PLGA (60kDa, 50 / 50) and TGF-β were prepared uniformly electrospray solution. The specific method is as follows: dissolve 60 mg of PLGA (60kDa, 50 / 50) in dichloromethane, seal it, let stand at 0°C overnight, stir magnetically for 4.5 hours, vortex for 15 minutes, and then sonicate for 30 seconds to eliminate air bubbles to obtain a PLGA solution; -β10ug was dissolved in 10mL of PBS buffer solution; 100μL of TGF-β-containing PBS solution was added to the PLGA solution, in an ice bath, ultrasonicated for 5s, stopped for 5s, and then ultrasonicated for 5s, repeated 10 times, emulsified to obtai...
PUM
| Property | Measurement | Unit |
|---|---|---|
| molecular weight | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More